Close Menu

Luminex

News items for the in vitro diagnostics industry for the week of Feb. 17, 2020. 

The firm said that its Verigene II multiplex system is on track to launch in mid-2020 among a number of new products scheduled for release this year. 

Qiagen, which is also developing a single-plex qRT-PCR assay for 2019-nCoV, said it will have a syndromic panel including targets for the virus ready this month.

The firm submitted its Verigene II Gastrointestinal Flex Assay to the FDA in Q4 and expects to submit Verigene II Respiratory Flex Assay to the agency in Q1 2020.

Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.

The company also said that preliminary full-year 2019 revenues are expected to be up 6 percent, with sample-to-answer revenues up more than 20 percent.

Luminex got the nod for a qualitative test used to simultaneously detect and identify nucleic acids from respiratory viruses and bacteria.

The firm said that total revenue was lower than expected due to the timing of orders in its flow cytometry operations in the third quarter.

The FDA gave the nod to Shenzhen Bioeasy Biotechnology for two lateral flow immunoassays that provide preliminary results in detecting marijuana in urine. 

The FDA clearance follows earlier US marketing approval for the firm's C. Difficile assay.

Pages